

---

## Heliospectra - Mixed outlook

Redeye provides an update following Heliospectra's Q2'23 report. We find the margin improvements, combined with a stronger-than-expected top line, to be encouraging. However, order intake fell short of our expectations, implying a weaker Dutch market and a mixed outlook in the near term. We have made a few minor changes to our near-term estimates. Our fair value range, however, remains unchanged, with a base case of SEK1.9 per share.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

[Heliospectra - Mixed outlook](#)